Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSNTI
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSenti Biosciences Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 26, 2021
āļāļĩāļāļĩāđāļLu (Timothy)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ34
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 26
āļāļĩāđāļāļĒāļđāđ2 Corporate Drive, First Floor
āđāļĄāļ·āļāļSOUTH SAN FRANCISCO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94080
āđāļāļĢāļĻāļąāļāļāđ16502392030
āđāļ§āđāļāđāļāļāđhttps://www.sentibio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSNTI
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 26, 2021
āļāļĩāļāļĩāđāļLu (Timothy)
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Feng Hsiung
Independent Director
Mr. Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Ms. Frances D. Schulz
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
Dr. Kanya Rajangam, M.D., Ph.D.
Dr. Kanya Rajangam, M.D., Ph.D.
President, Head - Research and Development, Chief Medical Officer
President, Head - Research and Development, Chief Medical Officer
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Dr. James J. (Jim) Collins, Ph.D.
Dr. James J. (Jim) Collins, Ph.D.
Independent Director
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Dr. Timothy (Tim) Lu, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director